Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | ERBB4 over exp |
Therapy | Idelalisib + Rituximab |
Indication/Tumor Type | marginal zone lymphoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB4 over exp | marginal zone lymphoma | resistant | Idelalisib + Rituximab | Preclinical - Cell culture | Actionable | In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to combination treatment with Rituxan (rituximab) and Zydelig (idelalisib) in culture (PMID: 38052765). | 38052765 |
PubMed Id | Reference Title | Details |
---|---|---|
(38052765) | ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms. | Full reference... |